Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Cives, M, Kunz, P L, Morse, B, Coppola, D, Schell, M J, Campos, T, Nguyen, P T, Nandoskar, P, Khandelwal, V, Strosberg, J R
Published in Endocrine-related cancer (01.02.2015)
Published in Endocrine-related cancer (01.02.2015)
Get full text
Journal Article
LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study
Agarwal, N., Azad, A.A., Galceran, J.C., Matsubara, N., Oudard, S., Saad, F., Merseburger, A.S., Soares, A., McGregor, B.A., Zurawski, B., Tsiatas, M., North, S., Bournakis, E., Antonuzzo, L., Williamson, D.S., Evilevitch, L., Simmons, A., Ferraldeschi, R., Nandoskar, P., Pal, S.K.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article